Evidence map›Paper›PMID 27038923›Full record

ArticleBMC molecular biology2016

Immunoblot screening of CRISPR/Cas9-mediated gene knockouts without selection.

Jason A Estep, Erin L Sternburg, Gissell A Sanchez, Fedor V Karginov

Abstract read
In one paragraph

Article in BMC molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jason A EstepDepartment of Cell Biology and Neuroscience, Institute for Integrative Genome Biology, University of California, Riverside, CA, 92521, USA.
Erin L SternburgDepartment of Cell Biology and Neuroscience, Institute for Integrative Genome Biology, University of California, Riverside, CA, 92521, USA.
Gissell A SanchezDepartment of Cell Biology and Neuroscience, Institute for Integrative Genome Biology, University of California, Riverside, CA, 92521, USA.
Fedor V KarginovDepartment of Cell Biology and Neuroscience, Institute for Integrative Genome Biology, University of California, Riverside, CA, 92521, USA. karginov@ucr.edu.

Funding

Acquisition of a Scalable Storage Cluster for Data Intensive NIH ResearchS10OD016290 · OD · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI GIRKE, THOMAS · 2014 to 2014
$593k
NIH HHS S10 OD016290
6 · The paper itself

Abstract

backgroundTargeted genomic editing using the CRISPR/Cas9 methodology has opened exciting new avenues in probing gene function in virtually any model system, including cultured mammalian cells. Depending on the desired mutation, several experimental options exist in the isolation of clonal lines, such as selection with introduced markers, or screening by PCR amplification of genomic DNA. However, streamlined approaches to establishing deletion and tagging mutants with minimal genomic perturbation are of interest in applying this methodology.

resultsWe developed a procedure for rapid screening of clonal cell lines for the deletion of a protein of interest following CRISPR/Cas9 targeting in the absence of selective pressure based on dot immunoblots. To assess the technique, we probed clonal isolates of 293-TREx cells that were targeted with three separate sgRNAs against the HuR gene. Validation of knockout candidates by western blot indicated that the normalized protein abundances indicated by the dot blot serve as accurate predictors of deletion. In total, 32 independent biallelic deletion lines out of 248 screened clones were isolated, and recovery of null mutants ranged from 6 to 36% for the individual sgRNAs. Genomic sequencing verified small deletions at the targeted locus.

conclusionsClonal screening for CRISPR/Cas9-mediated editing events using dot immunoblot is a straightforward and efficient approach that facilitates rapid generation of genomic mutants to study gene function.

Indexed as

CRISPR-Cas SystemsGene Knockout TechniquesGene TargetingImmunoblottingBase SequenceCell LineELAV-Like Protein 1GenotypeHumansMolecular Sequence DataMutationRNA, Guide, CRISPR-Cas SystemsSequence AlignmentELAV-Like Protein 1RNA, Guide, CRISPR-Cas SystemsClonal selectionCRISPR/Cas9Dot blotScreening

Identifiers

PMID27038923
PMCPMC4818936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.